Investment Rating - The report initiates coverage on Baiaosaitu (2315.HK) with a "Buy" rating and sets a target price of HKD 66.90, indicating a potential upside of 37.65% from the current price of HKD 48.60 [4][6][7]. Core Insights - Baiaosaitu is a technology-driven biotechnology company focused on gene editing, aiming to become a global source of new drugs. Its core business is divided into two main lines: preclinical products and services, and antibody molecule transfer and development, with the latter being highlighted by the "Thousand Mice, Ten Thousand Antibodies" program [2][16]. - The preclinical business is experiencing robust growth, benefiting from the enthusiasm for innovative research. In the first half of 2025, the preclinical products and services generated revenue of CNY 458 million, with innovative model animal sales increasing by 56% year-on-year [3][28]. - The "Thousand Mice, Ten Thousand Antibodies" business model, which includes upfront payments, milestone payments, and revenue sharing, is entering a harvest period, significantly shortening research and development timelines and improving clinical success rates [3][4]. Company Analysis - Baiaosaitu's preclinical products and services are expected to achieve revenues of CNY 1.86 billion and CNY 2.35 billion in 2026 and 2027, respectively, with year-on-year growth rates of 34.8% and 26.5% [4][5]. - The company has established a high barrier to entry with its innovative model animal sales, which are projected to grow from CNY 660 million in 2020 to CNY 389 million in 2024, reflecting a CAGR of 55.9% [17][18]. - The antibody development business is also on a growth trajectory, with revenues expected to rise from CNY 410 million in 2020 to CNY 318 million in 2024, achieving a CAGR of 66.8% [19][20]. Financial Forecast and Valuation - The report forecasts Baiaosaitu's revenue to reach CNY 1.86 billion in 2026 and CNY 2.35 billion in 2027, with gross margins of 76.68% and 77.53%, respectively [4][5]. - The net profit attributable to the parent company is projected to be CNY 331 million and CNY 500 million for 2026 and 2027, representing year-on-year growth of 91.4% and 51.0% [4][5]. - The current price corresponds to a 2026 PE ratio of 58 times, while the target price corresponds to a PE ratio of 80 times [4].

Investment Rating - The report initiates coverage on the company with a "Buy" rating and sets a target price of HKD 66.90, indicating a potential upside of 37.65% from the current price of HKD 48.60 [4][6][7]. Core Insights - The company, Baiaosaitu (2315.HK), is a technology-driven biotechnology firm focused on gene editing and aims to become a global source of new drugs. Its core business revolves around two main lines: preclinical products and services, and antibody molecule transfer and development through the "Thousand Mice, Ten Thousand Antibodies" program [2][16]. - The preclinical business is experiencing robust growth, benefiting from the enthusiasm for innovative research. In the first half of 2025, the preclinical products and services generated revenue of CNY 458 million, with innovative model animal sales reaching CNY 274 million, a year-on-year increase of 56% [3][28]. - The "Thousand Mice, Ten Thousand Antibodies" business model, which includes upfront payments, milestone payments, and revenue sharing, is entering a harvest phase, with expectations for significant revenue growth as the number of transferred antibody projects increases [3][4]. Summary by Sections Company Analysis - Baiaosaitu is positioned as a leading biotechnology company with a focus on gene editing technology, offering preclinical pharmacology and efficacy evaluation services, innovative model animal sales, and gene editing services [2][16]. - The antibody development business leverages the "Thousand Mice, Ten Thousand Antibodies" initiative to create a library of antibodies, providing licensing services that are expected to drive future growth [2][3]. Preclinical Business Growth - The preclinical pharmacology and efficacy evaluation services are expanding rapidly, with revenue projected to grow significantly due to the increasing demand for innovative research tools and services [3][28]. - The sales of model animals, particularly humanized mouse models, are a major revenue source, with sales expected to grow from CNY 66 million in 2020 to CNY 389 million in 2024, reflecting a CAGR of 55.9% [17][28]. Antibody Development - The antibody development segment is projected to grow from CNY 41 million in 2020 to CNY 318 million in 2024, with a CAGR of 66.8%, driven by the RenMice technology platform and a vast antibody library [19][20]. - The company has established a strong foothold in the overseas market, with international revenue increasing from CNY 91 million in 2020 to CNY 662 million in 2024, representing a CAGR of 64.3% [27][28].

Core Viewpoint - Baiaosaitu (688796) has successfully listed on the Sci-Tech Innovation Board, with its stock opening up 117.4% at 58 CNY per share [1] Company Overview - Baiaosaitu is an innovative drug preclinical CRO and biotechnology company, primarily providing antibody drug discovery and preclinical research services [1] - The company's services include the sale of innovative model animals, preclinical pharmacology and efficacy evaluation services, and antibody development [1] Stock Listing Details - Baiaosaitu previously issued H-shares in September 2022 and is listed on the Hong Kong Stock Exchange [1] - Following the A-share public offering, the company will have its stock listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange, with 75.21% of shares circulating in A-shares and 24.79% in H-shares [1] - The proportion of circulating shares in A-shares is higher than that in H-shares [1]

Core Viewpoint - BaiO Saite (688796) is set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, with an issue price of 26.68 yuan per share [2]. Company Overview - BaiO Saite is an innovative drug preclinical CRO and biotechnology company, primarily engaged in providing antibody drug discovery and preclinical research services for innovative drug enterprises [2]. - The company's specific services include the sale of innovative model animals, preclinical pharmacology and efficacy evaluation services, and antibody development [2].